GB201709222D0 - C3b Inactivating Polypeptide - Google Patents

C3b Inactivating Polypeptide

Info

Publication number
GB201709222D0
GB201709222D0 GBGB1709222.2A GB201709222A GB201709222D0 GB 201709222 D0 GB201709222 D0 GB 201709222D0 GB 201709222 A GB201709222 A GB 201709222A GB 201709222 D0 GB201709222 D0 GB 201709222D0
Authority
GB
United Kingdom
Prior art keywords
inactivating polypeptide
inactivating
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709222.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Priority to GBGB1709222.2A priority Critical patent/GB201709222D0/en
Publication of GB201709222D0 publication Critical patent/GB201709222D0/en
Priority to CN201880051653.9A priority patent/CN111051337A/zh
Priority to EP18729681.9A priority patent/EP3634985A1/en
Priority to JP2019567602A priority patent/JP7341897B2/ja
Priority to PCT/EP2018/065199 priority patent/WO2018224663A1/en
Priority to US16/620,383 priority patent/US20200277360A1/en
Priority to JP2023140001A priority patent/JP2023162355A/ja
Priority to US18/438,008 priority patent/US20240336675A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21045—Complement factor I (3.4.21.45)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1709222.2A 2017-06-09 2017-06-09 C3b Inactivating Polypeptide Ceased GB201709222D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1709222.2A GB201709222D0 (en) 2017-06-09 2017-06-09 C3b Inactivating Polypeptide
CN201880051653.9A CN111051337A (zh) 2017-06-09 2018-06-08 C3b灭活多肽
EP18729681.9A EP3634985A1 (en) 2017-06-09 2018-06-08 C3b inactivating polypeptide
JP2019567602A JP7341897B2 (ja) 2017-06-09 2018-06-08 Ｃ３ｂ不活性化ポリペプチド
PCT/EP2018/065199 WO2018224663A1 (en) 2017-06-09 2018-06-08 C3b inactivating polypeptide
US16/620,383 US20200277360A1 (en) 2017-06-09 2018-06-08 C3b inactivating polypeptide
JP2023140001A JP2023162355A (ja) 2017-06-09 2023-08-30 Ｃ３ｂ不活性化ポリペプチド
US18/438,008 US20240336675A1 (en) 2017-06-09 2024-02-09 C3b inactivating polypeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709222.2A GB201709222D0 (en) 2017-06-09 2017-06-09 C3b Inactivating Polypeptide

Publications (1)

Publication Number Publication Date
GB201709222D0 true GB201709222D0 (en) 2017-07-26

Family

ID=59358410

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709222.2A Ceased GB201709222D0 (en) 2017-06-09 2017-06-09 C3b Inactivating Polypeptide

Country Status (6)

Country Link
US (2) US20200277360A1 (enExample)
EP (1) EP3634985A1 (enExample)
JP (2) JP7341897B2 (enExample)
CN (1) CN111051337A (enExample)
GB (1) GB201709222D0 (enExample)
WO (1) WO2018224663A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB201821082D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
GB202006789D0 (en) 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
US12116606B2 (en) 2020-06-14 2024-10-15 Vertex Pharmaceuticals Incorporated Complement factor I-related compositions and methods
EP4214515A1 (en) 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
WO2023091875A1 (en) * 2021-11-19 2023-05-25 Ap Biosciences, Inc. Bi-functional fusion proteins to complement pathways and method of inhibiting bone resorption
CN114317562B (zh) * 2022-02-22 2023-06-13 辽宁省农业科学院 普通菜豆镰孢菌枯萎病抗病相关蛋白的编码基因PvEXO70及应用
GB202203627D0 (en) * 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044625A1 (en) * 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
GB9930659D0 (en) * 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
AU2007261315B2 (en) * 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
CN103249432A (zh) * 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
JP2016531910A (ja) * 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 移植前の臓器への補体阻害剤の投与による移植拒絶の処置
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
WO2016156466A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker

Also Published As

Publication number Publication date
US20240336675A1 (en) 2024-10-10
JP2023162355A (ja) 2023-11-08
CN111051337A (zh) 2020-04-21
WO2018224663A1 (en) 2018-12-13
JP2020527331A (ja) 2020-09-10
US20200277360A1 (en) 2020-09-03
EP3634985A1 (en) 2020-04-15
JP7341897B2 (ja) 2023-09-11

Similar Documents

Publication Publication Date Title
IL262482A (en) New polypeptides
IL275298B1 (en) Mitochondria-targeted peptides
GB201719557D0 (en) Polypeptide
GB201709222D0 (en) C3b Inactivating Polypeptide
GB201611530D0 (en) Novel polypeptides
GB201700557D0 (en) Novel peptides
AP00971S1 (en) Container
SG11202005653RA (en) Novel peptide
GB201707139D0 (en) Polypeptides
GB201619652D0 (en) Novel polypeptides
IL269477A (en) Polypeptides that bind to IL-1R-1
SG11202102378WA (en) Arginase1 polypeptides
GB201810052D0 (en) Polypeptide
GB2569037B (en) Cover
GB201817810D0 (en) Modified factor IX polypeptides
GB201719520D0 (en) Neuroprotectvie peptide
GB201620963D0 (en) Antimicrobial peptides
GB201716184D0 (en) Cover
GB201708471D0 (en) Polypeptide
GB201717958D0 (en) Novel polypeptides
GB201806655D0 (en) Polypeptide
GB201706915D0 (en) Novel polypeptides
GB201811755D0 (en) Polypeptides
GB2566016B (en) Container
GB201807893D0 (en) Polypeptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)